Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
Precision BioSciences (Nasdaq: DTIL) said it will publish first quarter 2026 financial results and provide a business update on May 5, 2026. The company is a clinical‑stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high‑unmet‑need diseases.
Precision BioSciences (Nasdaq: DTIL) activated Arkansas Children’s Hospital as the first clinical trial site and opened patient screening and enrollment for PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study on April 29, 2026. PBGENE-DMD targets DMD mutations between exons 45 and 55 and will assess safety, tolerability, dystrophin expression, and functional outcomes in ambulatory patients.
Arkansas Children’s is a PPMD-certified Duchenne Care Center and an MDA Care Center; additional sites are being activated to expand enrollment.
iECURE (NASDAQ:DTIL) will present preliminary clinical data for ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency at ASGCT (May 11-15, 2026) and SIMD (May 17-20, 2026).
Oral data cover the first three dose cohorts (n=7) and report a decreased rate of hyperammonemic crises. A SIMD poster shows one-year post-treatment data for the first infant who achieved a complete clinical response with sustained discontinuation of standard-of-care therapies.
Precision BioSciences (Nasdaq: DTIL) announced an oral presentation of new preclinical PBGENE-DMD data at the ASGCT 2026 Annual Meeting, May 11-15 in Boston.
The abstract reports efficacy in early-juvenile mice and builds on prior updates showing durable functional improvement in a humanized DMD mouse model. Presentation: May 14, 2026 at 8:45 a.m. ET; Presenter: Adam Michler Ph.D., DMD Research Lead; Session: Emerging molecular therapeutic strategies for muscular dystrophies.
Precision BioSciences (Nasdaq: DTIL) announced that on April 20, 2026 the Compensation Committee approved an inducement award of 7,094 restricted stock units (RSUs) for a newly hired employee under its 2021 Inducement Award Plan.
The RSUs vest in substantially equal annual installments on each of the first three anniversaries of the employee’s start date, subject to continued service.
Precision BioSciences (NASDAQ: DTIL) will present late-breaking biopsy data for PBGENE-HBV at EASL Congress 2026, showing evidence of elimination and inactivation of cccDNA in liver biopsies from the ongoing Phase 1 ELIMINATE-B trial.
The poster (LB26-51656 / LBP-043) will be presented by Man-Fung Yuen on May 27, 2026 at 8:30 CEST in Barcelona.
Precision BioSciences (Nasdaq: DTIL) received Clinical Trial Application approvals to expand the global ELIMINATE-B trial into France and Romania, adding European sites to existing locations in the UK, Moldova, New Zealand, Hong Kong and the US. Site initiation activities are underway and initial patient screening is expected in Q2 2026.
The expansion aims to support continued patient enrollment and clinical execution of PBGENE-HBV, a gene editing therapy designed to eliminate cccDNA, as the company advances the ELIMINATE-B trial.
Precision BioSciences (Nasdaq: DTIL) will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 9:30am ET. The presentation is virtual and will be webcast. A replay will be posted in the company's Investors section under Events and Presentations after the event.
If investors or analysts wish to request a meeting, contact your Needham representative.
iECURE (NASDAQ:DTIL) announced that ECUR-506, its investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, was selected for the FDA’s CMC Development and Readiness Pilot (CDRP) program.
Participation enables more frequent FDA engagement on CMC strategy ahead of a potential BLA, complements prior RMAT and Fast Track designations, and follows encouraging OTC-HOPE clinical data including a complete response in the first treated infant. Additional trial data is expected in H1 2026.
Precision BioSciences (Nasdaq: DTIL) reported Q4 and FY2025 results and provided clinical and corporate updates. Key highlights include PBGENE-HBV Phase 1 late-breaker data showing safety and dose-dependent antiviral activity, IND clearance for PBGENE-DMD in Feb 2026, and a $75M financing in Nov 2025.
The company ended 2025 with $137.2M cash, expects runway through 2028, reported Q4 revenue of $34.2M and full-year revenue of $34.3M, and received two patent Notices of Allowance extending PBGENE-HBV protection to Nov 2044.